Enterome is a clinical-stage company developing off-the-shelf, transformational cancer treatments targeting a wide range of tumor types. Ongoing Phase 2 trials for our most advanced programs, EO2463 and EO2401, have shown promising efficacy in non-Hodgkin lymphoma and recurrent glioblastoma, with good safety profiles in over 200 patients.
Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T cells, effectively overcoming immune tolerance to self-antigens. Watch our video here
Our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression from bench to bedside.
